

Strides receives USFDA tentative approval for Triamcinolone Acetonide Ointment

Product approval from flagship facility in Bangalore

To be marketed by Strides Pharma Inc. effective May 30, 2020

Bangalore, January 24, 2020 - Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received tentative approval for ***Triamcinolone Acetonide Ointment USP, 0.05%*** from the United States Food & Drug Administration (USFDA).

While it was amongst the few Competitive Generic Therapy (CGT) designated products for Strides, another generic company received approval prior to our approval. Consequently, the final approval for Strides will be effective 30 May 2020 when the company will launch the product.

According to IQVIA MAT data, the US market for Triamcinolone Acetonide Ointment USP, 0.05% is approximately US\$ 20 Mn. The product will be manufactured at the company's Oral dosage facility at Bangalore and will be marketed by Strides Pharma Inc. in the US market.

The company has 102 cumulative ANDA filings with USFDA of which 69 ANDAs have been approved and 33 are pending approval.

About Triamcinolone Acetonide Ointment

Triamcinolone Acetonide Ointment is in a class of medications called corticosteroids. It is used to treat the itching, redness, dryness, crusting, scaling, inflammation, and discomfort of various skin conditions, including psoriasis.

About Strides

Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India. The Company mainly operates in the regulated markets and has an "in Africa for Africa" strategy along with an institutional business to service donor-funded markets. The Company's global manufacturing sites are located in India- Bangalore (two locations), Pondicherry, and Chennai, Singapore, Italy- Milan, Kenya- Nairobi and United States-Florida. The Company focusses on "difficult to manufacture" products that are sold in over 100 countries. Additional information is available at the Company's website at www.strides.com

For further information, please contact:

Strides

Badree Komandur

Executive Director - Finance
+91 80 6784 0747

Investor Relations:

Kannan. N: +91 98450 54745

Vikesh Kumar: +91 80 6784 0827

Sandeep Baid: +91 80 6784 0791

Email: Sandeep.baid@strides.com

Strides Pharma Science Limited

(Formerly Strides Shasun Limited)

CIN: L24230MH1990PLC057062

Regd. Office: 201, 'Devavrata', Sector - 17,
Vashi, Navi Mumbai - 400 703

Corp. Office: Strides House, Bannerghatta
Road, Bangalore – 560 076

PR Consultancy

Fortuna PR

K Srinivas Reddy: +91 90005 27213
srinivas@fortunapr.com

K Priya: +91 95354 25418
priya@fortunapr.com